Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 8/20 | 0.59 |
| ▸ | ITK | Q08881 | 2/20 | 0.49 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1111640 | 0.92 | HPGDS (0.48) | HPGDSITKEPHX2HDAC2 | |
| SCHEMBL7999504 | 0.87 | DDR2 (0.45) | HPGDSITKHDAC2 | |
| SCHEMBL1111648 | 0.87 | ROCK2 (0.47) | HPGDSHTR2CMCHR1 | |
| SCHEMBL7987320 | 0.85 | ITK (0.49) | ITKEPHX2 | |
| SCHEMBL1111651 | 0.85 | ALDH1A1 (0.49) | — | |
| SCHEMBL12932955 | 0.84 | ERCC1 (0.51) | HDAC2 | |
| SCHEMBL1111610 | 0.84 | EPHX2 (0.49) | HPGDSEPHX2 | |
| SCHEMBL11981731 | 0.84 | ALDH1A1 (0.44) | EPHX2HDAC2 | |
| SCHEMBL12958860 | 0.84 | ALDH1A1 (0.48) | EPHX2 | |
| SCHEMBL1111647 | 0.84 | ALDH1A1 (0.44) | EPHX2HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102066356-B | Indoles as modulators of nicoticic acetylcholine receptor subtype alpha-7 | GLAXO GROUP LTD | 2014-06-11 | — | — | CN | claimed |
| US-8377941-B2 | Indoles as modulators of nicotinic acetylcholine receptor subtype alpha-7 | PROXIMAGEN LIMITED (GB) | 2013-02-19 | — | — | US | claimed |
| EP-2279183-B1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | PROXIMAGEN LTD (GB) | 2012-08-08 | — | — | EP | claimed |
| US-20110028486-A1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | GLAXOSMITHKLINE SERVICES UNLIMITED (GB) | 2011-02-03 | — | — | US | claimed |
| EP-2279183-A1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | Glaxo Group Limited (GB) | 2011-02-02 | — | — | EP | claimed |
| WO-2009127679-A1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | WO | claimed |
| CN-102066356-B | Indoles as modulators of nicoticic acetylcholine receptor subtype alpha-7 | GLAXO GROUP LTD | 2014-06-11 | — | — | CN | disclosed |
| US-8377941-B2 | Indoles as modulators of nicotinic acetylcholine receptor subtype alpha-7 | PROXIMAGEN LIMITED (GB) | 2013-02-19 | — | — | US | disclosed |
| US-20120252853-A1 | Positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2012-10-04 | — | — | US | disclosed |
| US-20120252853-A1 | Positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2012-10-04 | — | — | US | disclosed |
| US-20120252853-A1 | Positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2012-10-04 | — | — | US | disclosed |
| EP-2279183-B1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | PROXIMAGEN LTD (GB) | 2012-08-08 | — | — | EP | disclosed |
| US-20110028486-A1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | GLAXOSMITHKLINE SERVICES UNLIMITED (GB) | 2011-02-03 | — | — | US | disclosed |
| EP-2279183-A1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | Glaxo Group Limited (GB) | 2011-02-02 | — | — | EP | disclosed |
| WO-2009127679-A1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252853-A1 | Positive allosteric modulators of nicotinic acetylcholine receptor | CHRNG, CHRNA7, CHRNA2 | HPGDS 3088/4885ITK 3985/4885BAZ2B 1410/4885 |
| US-20110028486-A1 | INDOLES AS MODULATORS OF NICOTICIC ACETYLCHOLINE RECEPTOR SUBTYPE ALPHA-7 | CHRNA7, CHRNA5, CHRNA6 | HPGDS 4472/4885ITK 3116/4885BAZ2B 1472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.